Our Board of Directors
Our Board is collectively responsible for the success of the Company. As an AIM listed company the Board is committed to achieving high standards of corporate governance, integrity and business ethics.
Find out information about or Senior Leadership Team here.
David joined the board of Alliance as a non-executive director in 2014 and was appointed Chairman of the Board on the 1 March 2018. He is currently Chief Financial Officer and an Executive Director of Ellipses Pharma, an international cancer drug development company, and was previously Chief Financial Officer and Chief Business Officer of Biotie Therapies Corp, a drug development company quoted in Helsinki and on NASDAQ. He has previously held senior financial positions with Jazz Pharmaceuticals International, EUSA Pharma and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford.
David has extensive experience of financial and general business management (including the implementation of buy and build strategies) in the life sciences sector, of financing those businesses and managing investor relations across a number of stock markets globally.
Peter was previously the company’s Deputy Chief Executive Officer and was appointed to his present office as Chief Executive Officer on the 1 May 2018 having joined Alliance in 2010 as an executive director. He served eight years as a Board Member of the Association of the British Pharmaceutical Industry and was an integral part of the 2014 PPRS negotiation team with the UK Government. Peter joined the board of Alliance in 2010 with the acquisition of Cambridge Laboratories where he spent five years, latterly as UK Commercial Director. Prior to joining Cambridge Laboratories, Peter spent six years at GlaxoSmithKline in a variety of marketing and sales roles. He holds an honours degree in Pharmacology from the University of Edinburgh.
Peter has over 20 years’ experience in the life sciences sector and strong leadership experience gained in a variety of contexts.
Andrew joined Alliance in September 2015 from Panasonic Europe Ltd, where he was General Manager, European Tax and Accounting. From 2010 to 2012 Andrew was Finance Director and Company Secretary of Genzyme Therapeutics Ltd, the UK & Ireland subsidiary of Genzyme Corporation. Prior to that, he gained 12 years pharmaceutical experience with Wyeth in a variety of senior financial positions. Andrew holds an honours degree in Civil Engineering from the University of Wales, Cardiff.
Andrew is a Fellow of the Institute of Chartered Accountants in England and Wales with extensive experience of financial management of international businesses, including significant prior experience in life science companies.
Jo has 25 years’ healthcare management experience gained in Europe, the US and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernise the commercial model. She was previously Chief Operating Officer at the BMI group of private hospitals in the U.K. She was non-executive director at Frimley Park NHS Foundation Trust in the UK, Duke NUS Medical School in Singapore and Cello Health plc.
She is currently a Non-Executive Director at UK listed companies Circassia Group plc and is also on the board of Recordti S.p.a. Jo is a graduate of Cambridge University and a Chartered Accountant.
Richard joined Alliance as a Non-Executive Director on 1st January 2019. Recently, he was appointed Chief Financial Officer at UK main market listed Medica Group PLC, the UK’s market leading teleradiology provider. Before this, Richard gained extensive experience in the healthcare sector in his roles as CFO at UK AIM Listed companies Mereo BioPharma Group PLC and Shield Therapeutics PLC. At Mereo, he had a leading role in the merger with US listed OncoMed Pharmaceuticals, Inc and Mereo’s dual listing on Nasdaq in 2019. At Shield he had a leading role establishing the finance operations and guiding Shield through its 2016 IPO.
His prior career in investment banking included senior positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC in 1991.